STANDARD BIOTOOLS INC. SEC Filings

STANDARD BIOTOOLS INC. senior vice president and chief business officer Sean Mackay reported a routine tax-withholding transaction. On May 20, 2026, 25,729 shares of common stock were withheld to satisfy tax obligations arising from vested restricted stock units granted on May 20, 2024, March 21, 2025 and March 20, 2026.

Following this withholding, Mackay directly holds 1,006,552 shares of common stock. This Form 4 reflects compensation-related tax settlement rather than an open-market purchase or sale.

STANDARD BIOTOOLS INC. President & CEO Michael Egholm reported a tax-related share disposition. On May 20, 2026, 97,626 shares of common stock were withheld to satisfy tax withholding obligations arising from the vesting of previously granted restricted stock units. These grants were originally awarded on May 20, 2024, March 21, 2025 and March 20, 2026. After this withholding, Egholm directly holds 6,597,956 shares of common stock, indicating this was a compensation- and tax-driven event rather than an open-market trade.

MAK Capital and related entities reported beneficial ownership of 26,172,626 shares of Standard BioTools Inc. common stock, representing 6.7% of the class. The filing states the share count is as of 05/15/2026 and references 390,368,119 shares outstanding as of May 4, 2026.

The Schedule 13G/A lists shared voting and dispositive power over the 26,172,626 shares and identifies MAK Capital Fund LP, MAK Capital One L.L.C., and Michael A. Kaufman as reporting persons. Signatures are dated 05/15/2026.

Standard BioTools Amendment No. 2 to a Schedule 13G/A: Viking Global Investors and affiliated entities report beneficial ownership of 58,651,170 shares of Common Stock. The filing states this represents 15.0% of 390,141,000 shares outstanding as of March 31, 2026. The amendment removes David C. Ott as a reporting person effective March 31, 2026.

The disclosure breaks the position into 39,296,310 shares held through Viking Global Opportunities (VGOP) and 19,354,860 shares held through Viking Global Opportunities Drawdown (VGOD), and shows shared voting and dispositive power across the listed Viking entities and two executive committee members.

Standard BioTools Inc. reported Q1 2026 results showing modest growth in its core tools business and a large one-time gain from selling its SomaScan proteomics business to Illumina.

Revenue from continuing operations was $21.1 million, up 5% year over year, driven by 35% higher consumables sales, while instrument revenue fell 33%. The company posted a net loss from continuing operations of $14.6 million but overall net income of $127.1 million due to a $172.3 million pre-tax gain on the SomaScan sale, recorded in discontinued operations.

Cash, cash equivalents and investments rose to about $526.5 million, reflecting $363.2 million of cash proceeds from the divestiture plus a $25.0 million contingent receivable and potential future earnouts up to $50.0 million. Operating expenses declined 37% as restructuring and prior-year integration efforts reduced R&D and SG&A, though the company continues to incur restructuring charges. The filing also notes a Nasdaq minimum bid-price deficiency notice, creating a risk of future delisting if compliance is not restored.

Standard BioTools Inc. reported first quarter 2026 results with revenue of $21.1 million, up 5% year-over-year, and a sharply reduced operating loss of $12.5 million. Net loss from continuing operations improved to $14.6 million, while adjusted EBITDA loss narrowed to $3.1 million from $14.1 million.

Product trends were mixed: consumables revenue rose 35% to $11.0 million, services grew 5% to $5.7 million, and instruments declined 33% to $4.5 million amid capital-constrained end markets. Operating expenses fell 37% to $23.8 million, reflecting restructuring actions.

The completed sale of SomaLogic drove $141.7 million income from discontinued operations and total net income of $127.1 million. Cash, cash equivalents, restricted cash, and liquid investments reached $523.6 million as of March 31, 2026. The company continues to expect full year 2026 revenue of $80–$85 million.

Standard BioTools Inc. is asking stockholders to vote at its 2026 virtual annual meeting on June 17, 2026 at 11:30 a.m. Eastern Time. Proposals include electing three Class I directors, an advisory say‑on‑pay vote, ratifying PwC as auditor, approving a new 2026 Equity Incentive Plan, and adding 1,200,000 shares to the 2017 Employee Stock Purchase Plan.

The proxy highlights a 2025 divestiture of SomaLogic and related units to Illumina for up to $425 million plus 10 years of royalties, with continuing-operations revenue of $85.3 million and $210.7 million in cash and investments as of December 31, 2025, rising to about $550 million after the deal closing in January 2026. It also describes board structure, governance practices, risk oversight, executive compensation philosophy, and strong 2025 say‑on‑pay support of approximately 98.29%.

Standard BioTools Inc. received a notice from Nasdaq that its common stock no longer meets the exchange’s $1.00 minimum bid price requirement after trading below that level for 30 consecutive business days.

The stock continues to trade on the Nasdaq Global Select Market under “LAB” while the company has 180 calendar days, until October 19, 2026, to regain compliance by having a closing bid price at or above $1.00 for at least 10 consecutive business days. If all other listing standards are met, the company may seek an additional 180‑day period by transferring to the Nasdaq Capital Market. Potential remedies mentioned include a reverse stock split. The company intends to work toward restoring compliance but notes there is no assurance it will succeed or receive any extension.